1. health and fitness
2. disease

®
Dextromethorphan/Quinidine (Nuedexta) – CLINICIAN INFORMATION
August 4, 2011
What is the medication?
Generic: Dextromethorphan hydrobromide/Quinidine sulfate (DM/QS)
Brand name: Nuedexta
Has the medication received US Food and Drug Administration (FDA) approval?
Yes – approved on October 29, 2010: Fixed–dose combination capsules containing DM
20 mg/QS 10 mg taken by mouth once daily for 7 days, then one capsule every 12 hours
thereafter.
If so, what are the indications and uses?
• Indicated for the treatment of pseudobulbar affect (PBA), which is defined by
involuntary, sudden, and frequent episodes of laughing and/or crying that are
generally out of proportion or inappropriate to the situation.
• Studies to support the effectiveness of DM/QS were performed in patients with
underlying amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). Although
DM/QS has not been shown to be safe or effective in other types of emotional
lability that can commonly occur – for example, in Alzheimer’s disease and other
dementias – DM/QS is approved for treatment of PBA regardless of the underlying
medical condition.
• Use is not approved for other types of emotional lability.
• Use is not restricted to any particular disease course of MS.
• Safety and effectiveness in patients under 18 years of age have not been established.
What were the findings in the pivotal and supportive trials of this medication?
Approval was based on efficacy and safety data from four phase 3 trials and additional,
uncontrolled studies of PBA. Relevant published trials include Brooks et al. (Neurology
2004;63:1364-1370), Panitch et al. (Ann Neurology 2006;59:780-787), and Pioro et al.
(Ann Neurol 2010;68:693-702). Only the Pioro et al study (discussed below) included
subjects who received the currently approved fixed-dose combination.
Trial Design: One phase 3, 12-week, placebo-controlled, double-blind trial
randomized 326 patients with either MS (40%) or ALS (60%) to treatment with
DM 30 mg/QS 10mg, DM 20 mg/QS 10 mg, or placebo (1:1:1). All subjects had a
baseline score of ≥ 13 on the Center for Neurologic Studies - Lability Scale (CNSLS) and were 18–80 years of age. ALS was diagnosed within the previous 30
MS COALITION
(800)532-7667 x 112 [email protected]
www.ms-coalition.org/emergingtherapies
1 of 9
®
months by the El Escorial criteria, and MS or probable MS was diagnosed by 2001
McDonald criteria. Patients took the medication or placebo once daily for the first
week and twice daily for the remaining weeks of the trial.
Primary Endpoint: Change in the daily number of episodes of PBA from baseline
as recorded in the patient’s diary at either dose of DM/QS when compared with
placebo.
Secondary Endpoints: Change from baseline scores on the CNS-LS, the Beck
Depression Inventory-II (BDI-II), the Neuropsychiatric Inventory (NPI), and the
Medical Outcomes Study 36-Item Short-Form Health Survey Version 1.0 (SF-36).
Results:
-- The primary outcome measure, laughing and crying episodes, was significantly
lower for patients on both fixed doses of DM/QS as compared with those
on placebo (46.9% and 49.0%, respectively, for the higher and lower DM
formulations).
-- Mean CNS-LS scores decreased 8.2 points for both the higher and lower DM
formulations as compared with 5.7 points for those on placebo.
-- When compared with the placebo group, both the higher- and lower-dose
treatment groups were about 60% more likely to experience a complete remission
of PBA episodes during the last 2 weeks of treatment.
What is the mechanism of action and the rationale for the use in MS?
• The exact mechanism of action for the effect of DM/QS on PBA is unknown.
• DM is a dextrorotatory analogue of levorphanol. It is a σ-1 receptor agonist as
well as a noncompetitive inhibitor of the excitatory NMDA receptor. Blocking σ-1
receptors inhibits glutamate release and, along with the noncompetitive inhibition
of the NMDA glutamate receptor, would lead to an inhibition of excitatory synaptic
transmission. It is not clear how that leads to inhibition of PBA symptoms.
• There is a theory that PBA is caused by abnormalities of cortical-pontine-cerebellar
pathways that involve glutaminergic transmission (Miller et al, 2011).
What is the delivery route and recommended dosing?
• DM 20 mg/QS 10 mg as one capsule taken once per day for 7 days, then one capsule
taken every 12 hours thereafter.
• Capsules should be taken whole, without having been broken or crushed.
Dextromethorphan/Quinidine (Nuedexta) – CLINICIAN INFORMATION
2 of 9
®
Can this medication be used with other medications?
• Disease-modifying Therapies (DMT):
-- DM/QS was used along with interferon-β or glatiramer acetate by some patients
with MS participating in the Panitch et al 2006 study. No altered tolerance of the
combination was reported.
-- There are no published data on experiences with other FDA-approved DMTs
such as natalizumab or fingolimod.
-- Given that fingolimod can induce bradycardia and first-degree heart block, and
given that QS can increase the QT interval, caution when combining these agents
is advised.
• Other Medications:
-- DM/QS should not be used with other medications containing quinidine,
quinine, or mefloquine. These include a number of nonprescription, over-the
counter medications containing either DM or quinidine or similar medications.
-- DM/QS should not be used in patients taking monoamine oxidase inhibitors
(MAOIs), and use with selective serotonin reuptake inhibitors (SSRIs) or tricyclic
antidepressants may increase the risk of serotonin syndrome.
-- QS is a potent inhibitor of cytochrome P450 2D6 and should not be used with
other medications that prolong the QT interval and are metabolized by CYP2D6,
including thioridazine and pimozide.
-- DM/QS should be used with caution with any medications that can prolong the
QT interval and inhibit CYP3A4, particularly in patients with cardiac disease.
How does the expected treatment effect compare with the treatment effect provided by
other available medications?
No direct comparisons have been made of DM/QS with any other medications used
to treat PBA. Although there have been studies reporting success in treating PBA with
other agents, including low doses of amitriptyline, there are no other FDA-approved
medications for the treatment of PBA.
What are the possible short–term side effects? What is the range of severity of side effects,
and what are the recommended management strategies?
• In combined studies at different test doses, side effects that were seen in >3% of
patients and at an incidence of >2 times the rate seen in the placebo group in shortterm trials included diarrhea, dizziness, vomiting, asthenia, peripheral edema,
urinary tract infections, increased gamma-glutamyltransferase, and flatulence.
Dextromethorphan/Quinidine (Nuedexta) – CLINICIAN INFORMATION
3 of 9
®
• In one study that included patients with MS and patients with ALS, dizziness, nausea,
diarrhea, and urinary tract infections were more frequent in the DM 30 mg/QS 10
mg group but not in the DM 20 mg/QS 10 mg group as compared with the placebo
group. In the study limited to patients with MS, dizziness was more common in
patients treated with DM 30 mg/QS 30 mg, but there was no statistical difference
relative to placebo-treated patients for any other side effect.
• Immune-mediated thrombocytopenia can be caused by quinidine and can range
from mild to severe, even leading to death. Nonspecific symptoms—including
lightheadedness, chills, fever, nausea, and vomiting—can occur and can precede
the evidence of thrombocytopenia. DM/QS should be stopped immediately if the
patient experiences the above symptoms while on treatment. Thrombocytopenia
may clear spontaneously in a few days, but careful monitoring is required. Cross
reaction occurs with structurally related agents, including quinine and mefloquine.
Re-challenge should not be attempted, as a more rapid and severe thrombocytopenia
may occur.
• QS has been associated with a lupus-like syndrome with positive antinuclear
antibodies, although not in the studies with DM/QS. Other side effects of
QS—including rash, lymphadenopathy, vasculitis, uveitis, hemolytic anemia,
bronchospasm, angioedema, agranulocytosis, sicca complex, myalgias, elevation of
serum levels of muscle enzymes, and pneumonitis—have been reported, although
not in studies of DM/QS.
• QS has been associated with hepatitis, including granulomatous hepatitis, generally
in the first 2 weeks of therapy. The infection may be accompanied by fever and
thrombocytopenia. Treatment consists of withdrawal of the medication. This side
effect was not seen in the short-term studies in the neurologic patients treated with
DM/QS.
• Cardiac effects are well reported with QS, including dose-dependent QTc
prolongation, and can lead to torsades de pointes-type ventricular tachycardia.
Patients at risk of developing prolonged QTc or torsades de pointes-type ventricular
tachycardia should have a baseline ECG performed, followed by a repeat ECG 3–4
hours after the first dose. Risk factors include diagnosis of cardiac disease with leftventricular hypertrophy or dysfunction, use of medications known to prolong the
QT interval or to be strong or moderate CYP3A inhibitors (including atazanavir,
clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir,
ritonavir, saquinavir, telithromycin, amprenavir, aprepitant, diltiazem, erythromycin,
fluconazole, fosamprenavir, and verapamil), or consumption of grapefruit juice.
Dextromethorphan/Quinidine (Nuedexta) – CLINICIAN INFORMATION
4 of 9
®
• Reevalution should be done if symptoms suggestive of cardiac disease occur,
bradycardia medications that prolong QT are added, or hypokalemia and
hypomagnesemia occur.
• Serotonin syndrome can occur if this medication is combined with tricyclic or SSRI
antidepressants. Patients in studies were not taking any of these agents during the
study period.
• Anticholinergic effects of QS could theoretically cause problems in myasthenia gravis
or other diseases that are adversely affected by anticholinergic agents.
What are the known long-range (morbidity- and mortality-related) health risks?
• DM has potential for abuse, although abuse was not observed in these relatively
short-term studies. Abuse and drug seeking with DM have been more frequent in
adolescents.
• As noted there are multiple known risks in the use of QS, including
thrombocytopenia and cardiac effects.
Has the FDA included any black box warnings about this medication?
There are no black box warnings for DM/QS.
What training is recommended or required for clinicians or patients before initiation of
this treatment?
No specific training is required for clinicians or patients
What is the pregnancy rating for this medication, and what is known about possible
carcinogenesis, mutagenesis, and impairment of fertility?
• This medication is classified as Category C. There are no well-controlled studies of
DM/QS in pregnant women. DM/QS was shown to be teratogenic and to increase
intrauterine death when given to pregnant animals.
• DM/QS should only be used during pregnancy when potential benefits justify the
risk to the fetus, particularly since this is not a disease-modifying therapy.
• There are no data on excretion of DM or QS in breast milk, so risks associated with
breastfeeding are not known.
• DM and QS have no known effects on carcinogenesis, mutagenesis, or fertility.
Does this medication interact or interfere with oral contraceptives?
There is no known interaction or interference with oral contraceptives.
Dextromethorphan/Quinidine (Nuedexta) – CLINICIAN INFORMATION
5 of 9
®
Has the FDA required a safety-monitoring program?
The FDA has not required a safety-monitoring program.
What kind of safety monitoring is recommended (including prescreening, routine
checkups, and laboratory tests)?
• DM/QS should not be used by patients with a prior history of hypersensitivity
to DM, quinidine, quinine, or mefloquine, or who have had quinidine-induced
thrombocytopenia, hepatitis, bone marrow depression, or lupus-like syndrome.
• DM/QS should not be used in patients with a prolonged QT interval, congenital long
QT syndrome, a history suggestive of torsades de pointes, or heart failure.
• DM/QS should not be used in patients receiving MAOIs or in patients who have
taken MAOIs within the preceding 14 days.
• DM/QS should not be taken by patients receiving medications that both prolong QT
interval and are metabolized by CYP2D6, such as thioridazine and pimozide.
• DM/QS should not be given to patients with complete AV block without implanted
pacemakers or who are at a high risk of complete AV block.
• No routine blood tests are required or suggested prior to starting treatment or
during therapy with DM/QS, but ECG should be performed. Repeat ECG should be
performed if a patient develops a risk factor for prolonged QT interval or AV block.
• Close monitoring should be done in patients who are taking antidepressants (SSRIs
or tricyclics), digoxin, or CYP2D6 inhibitors, or in patients who develop electrolyte
imbalance or hypomagnesaemia.
• There are no data on use in pediatric patients. While patients over 65 years of age
were included in the studies of DM/QS, the numbers were small; therefore, it is not
known if patients over 65 years of age respond differently than younger patients.
• There have been no problems with the use of DM/QS in patients with mild to
moderate renal or hepatic dysfunction; there are no data on patients with severe
renal or hepatic dysfunction.
Are there any recommended limits on treatment duration with this medication?
There are no recommended limits on duration of treatment with this medication.
What happens following termination of treatment with this medication?
DM/QS can be discontinued at any time. PBA symptoms would be expected to persist
or return after discontinuation of the medication.
Dextromethorphan/Quinidine (Nuedexta) – CLINICIAN INFORMATION
6 of 9
®
What treatment options are available for patients who have been treated with DM/QS?
There are no other FDA-approved medications to decrease occurrence of PBA episodes.
There are studies demonstrating some benefit with the use of low doses of amitriptyline.
What is the washout period?
When DM 30 mg/QS 30 mg is administered to individuals with normal CYP2D6
function, the half-life of DM is approximately 13 hours and of QS approximately 7
hours. No information is available regarding the half-life of the approved dose.
How can the provider identify a suboptimal treatment response?
• There are no firm criteria for determining a suboptimal response. It will be necessary
to work with the patient and family to see whether there is a decrease in PBA
episodes.
• A small percentage of individuals have a mutation in the gene for CYP2D6 that
prevents QS or any other CYP2D6 inhibitors from blocking this enzyme function.
When the mutation is present DM is rapidly metabolized, and DM/QS does not have
a therapeutic effect on PBA.
Is the manufacturer/distributor offering any financial assistance program for patients?
Avanir Pharmaceuticals, Inc. has a program to limit patient copayment obligations for
eligible patients (call 1-855-4NUEDEX [1-855-468-3339]).
Are there any special considerations with this medication?
DM/QS can be used by patients with any clinical MS type (relapsing-remitting,
secondary progressive, primary progressive, progressive relapsing) for the indication of
symptomatic management of PBA.
Dextromethorphan/Quinidine (Nuedexta) – CLINICIAN INFORMATION
7 of 9
®
COMMENTARY BY TEMPLATE AUTHORS
• Appropriate patient selection is extremely important when prescribing this
medication and monitoring its outcome. It may be helpful to include both the
patient and family during the initial encounter, to educate them on use of the
medication, and during follow-up visits, to determine response to therapy. Baseline
estimates and follow-up notes or communication documenting responses are advised
for continued use of a medication that may not benefit all patients with PBA.
• Although not explicitly required, establishment of a baseline ECG seems prudent
prior to starting treatment with DM/QS. Establishment of a baseline CBC, BUN/
creatinine, LFTs, electrolytes, and magnesium should also be considered, particularly
if there are reasons to suspect abnormalities.
• Many patients with MS have depression and/or anxiety and are using
antidepressants. The combination of these medications with DM/QS could be
problematic.
• The combined use of DM/QS (which can cause prolonged QT interval) and
fingolimod (the initial dose of which can cause various degrees of heart block and
bradycardia) should be undertaken with great caution.
• Because patients with MS may be taking a number of prescribed or over-the-counter
medications, it is essential to obtain a complete medication profile before this
medication is started.
WEB LINKS PROVIDED IN THIS DOCUMENT
• FDA prescribing information - http://www.nuedexta.com/pdf/Prescribing%20
Information.pdf
• Brooks et al., 2004 – http://www.ncbi.nlm.nih.gov/pubmed/15505150.
• Panitch et al, 2006 – http://www.ncbi.nlm.nih.gov/pubmed/16634036
• Pioro et al, 2010 – http://www.ncbi.nlm.nih.gov/pubmed/20839238
• Moore et al, 1997 – http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2169647/pdf/
v063p00089.pdf
•
Miller et al, 2011 – http://www.ncbi.nlm.nih.gov/pubmed?term=miller%20
AND%20pseudobulbar%20affect%20AND%202011
Dextromethorphan/Quinidine (Nuedexta) – CLINICIAN INFORMATION
8 of 9
®
AUTHORS:
June Halper, MSN, APN-C, FAAN, Robert Lisak, MD, Jerry Wolinsky, MD
EDITOR:
Rosalind Kalb, PhD
DISCLAIMER:
The Emerging Therapies Collaborative is proud to be a source of information about multiple
sclerosis. Our comments are based on published data and expert opinion, but do not represent
individual therapeutic recommendations or prescriptions. For specific information and advice,
consult your physician.
FOR DISCLOSURES AND OTHER INFORMATION:
Please visit our website at http://www.ms-coalition.org/emergingtherapies or email us at
[email protected].
For additional information, healthcare professionals are invited to email the National MS
Society’s Professional Resource Center at [email protected].
9 of 9